Stock Track | Akero Therapeutics Plummets 8.06% on Disappointing Phase 2b Trial Results for Efruxifermin in MASH

Stock Track11-16

Shares of Akero Therapeutics (AKRO) dropped sharply in the pre-market session on Friday, plummeting around 8.06%. The biopharmaceutical company focused on developing treatments for serious metabolic diseases faced a setback as it presented the results of its Phase 2b HARMONY study for its lead candidate efruxifermin (EFX) in metabolic dysfunction-associated steatohepatitis (MASH) at the 75th Annual AASLD The Liver Meeting®.

While the results showed some promising signs of anti-fibrotic effects and disease reversal with EFX treatment, the overall data failed to meet the high expectations of investors and analysts. The company highlighted that 42% of participants receiving the higher 50mg dose of EFX for 96 weeks showed improvement in liver fibrosis across multiple measures, including conventional histopathology, imaging biomarkers, and serum biomarkers. However, this figure was lower than anticipated, and the lower 28mg dose showed even weaker results.

Analysts expressed concerns about the efficacy and potential differentiation of EFX in the highly competitive MASH market. Despite Akero's claims of consistent anti-fibrotic effects and a favorable safety profile, investors seem to have been disappointed by the lack of more compelling data to support EFX's potential as a transformative therapy in this indication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195415335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-16 00:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195415335","market":"us","top_or_hot":-1,"title":"Stock Track | Akero Therapeutics Plummets 8.06% on Disappointing Phase 2b Trial Results for Efruxifermin in MASH","media":"Stock Track","content":"<p>Shares of Akero Therapeutics (AKRO) dropped sharply in the pre-market session on Friday, plummeting around 8.06%. The biopharmaceutical company focused on developing treatments for serious metabolic diseases faced a setback as it presented the results of its Phase 2b HARMONY study for its lead candidate efruxifermin (EFX) in metabolic dysfunction-associated steatohepatitis (MASH) at the 75th Annual AASLD The Liver Meeting®.</p>\n\n<p>While the results showed some promising signs of anti-fibrotic effects and disease reversal with EFX treatment, the overall data failed to meet the high expectations of investors and analysts. The company highlighted that 42% of participants receiving the higher 50mg dose of EFX for 96 weeks showed improvement in liver fibrosis across multiple measures, including conventional histopathology, imaging biomarkers, and serum biomarkers. However, this figure was lower than anticipated, and the lower 28mg dose showed even weaker results.</p>\n\n<p>Analysts expressed concerns about the efficacy and potential differentiation of EFX in the highly competitive MASH market. Despite Akero's claims of consistent anti-fibrotic effects and a favorable safety profile, investors seem to have been disappointed by the lack of more compelling data to support EFX's potential as a transformative therapy in this indication.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Akero Therapeutics Plummets 8.06% on Disappointing Phase 2b Trial Results for Efruxifermin in MASH</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Akero Therapeutics Plummets 8.06% on Disappointing Phase 2b Trial Results for Efruxifermin in MASH\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-16 00:08 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Akero Therapeutics (AKRO) dropped sharply in the pre-market session on Friday, plummeting around 8.06%. The biopharmaceutical company focused on developing treatments for serious metabolic ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKRO","symbol_name":"Akero Therapeutics","start_time":0,"source_url":"","article_id":"1195415335","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195415335","pubTimestamp":1731686910,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Akero Therapeutics  dropped sharply in the pre-market session on Friday, plummeting around 8.06%. The biopharmaceutical company focused on developing treatments for serious metabolic diseases faced a setback as it presented the results of its Phase 2b HARMONY study for its lead candidate efruxifermin  in metabolic dysfunction-associated steatohepatitis  at the 75th Annual AASLD The Liver Meeting.While the results showed some promising signs of anti-fibrotic effects and disease reversal","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AKRO":"Akero Therapeutics"},"translate_title":"Akero Therapeutics因MASH中Efruxifermin的2b期试验结果令人失望而暴跌8.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKRO":1},"content_text":"Shares of Akero Therapeutics (AKRO) dropped sharply in the pre-market session on Friday, plummeting around 8.06%. The biopharmaceutical company focused on developing treatments for serious metabolic diseases faced a setback as it presented the results of its Phase 2b HARMONY study for its lead candidate efruxifermin (EFX) in metabolic dysfunction-associated steatohepatitis (MASH) at the 75th Annual AASLD The Liver Meeting®.\nWhile the results showed some promising signs of anti-fibrotic effects and disease reversal with EFX treatment, the overall data failed to meet the high expectations of investors and analysts. The company highlighted that 42% of participants receiving the higher 50mg dose of EFX for 96 weeks showed improvement in liver fibrosis across multiple measures, including conventional histopathology, imaging biomarkers, and serum biomarkers. However, this figure was lower than anticipated, and the lower 28mg dose showed even weaker results.\nAnalysts expressed concerns about the efficacy and potential differentiation of EFX in the highly competitive MASH market. Despite Akero's claims of consistent anti-fibrotic effects and a favorable safety profile, investors seem to have been disappointed by the lack of more compelling data to support EFX's potential as a transformative therapy in this indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195415335"}